Investigational drug · Phase 3
AT-001
Also called: NACA, NAC-amid
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain, Hemorrhage Cerebral.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "AT-001"
First trial start
2019
Sep 20, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AT-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
- Hemorrhage Brain
- Hemorrhage Cerebral
- Diabetic Cardiomyopathies
Approved drugs for the same conditions: Cardiovascular and metabolic · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "AT-001" as an intervention, largest first.
- Safety and Efficacy of AT-001 in Patients With Diabetic CardiomyopathyPivotal-lookingActive, not recruiting
Applied Therapeutics, Inc.Industry
NCT04083339 · 675 participants (planned) · Start Sep 20, 2019 · Primary completion Dec 2023
Drug: AT-001; Placebo · For: Diabetic Cardiomyopathies
Sites: Beverly Hills, California; La Jolla, California; Lincoln, California · 79 sites in all
- Cardiovascular Effects of COVID-19Completed
NYU Langone HealthAcademic, hospital or other
NCT04365699 · 81 participants · Start Apr 8, 2020 · Primary completion Jan 31, 2021
Drug: AT-001 · For: COVID-19
Sites: New York, New York
- Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)Active, not recruiting
Arctic TherapeuticsIndustry
NCT07741526 · 33 participants · Start Oct 14, 2025 · Primary completion Apr 30, 2027
Drug: NPI-001; Placebo · For: Alzheimer´s Disease
Sites: Gandrup, Denmark; Herlev, Denmark; Vejle, Denmark · 4 sites in all
Alltech Life Sciences Inc.Industry
NCT01731093 · 24 participants · Start Mar 2012 · Primary completion Oct 2013
Drug: AT-001; Placebo · For: Oxidative Stress
Sites: Lexington, Kentucky
- Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)Active, not recruiting
Arctic TherapeuticsIndustry
NCT07716865 · 15 participants · Start Apr 3, 2024 · Primary completion Dec 29, 2026
Drug: NACA · For: Hereditary Cystatin C Amyloid Angiopathy (HCCAA); Hemorrhage Brain; Hemorrhage Cerebral
Sites: Reykjavik, Iceland
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05041101 · 6 participants · Start Dec 21, 2021 · Primary completion Sep 6, 2024
Drug: Eribulin Mesylate; Grapiprant · For: Breast Inflammatory Carcinoma; Recurrent Breast Inflammatory Carcinoma; Stage IV Breast Inflammatory Carcinoma
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- A binary electrolyte strategy coupling cl- and citrate to regulate anodic dissolution dynamics for high-performance aqueous Mg-air batteries.
Zhang W, He C, Chai Y, et al. · J Colloid Interface Sci 2027
- Evolving vortex dynamics around a pitching wing for dynamic stall at a transitional Reynolds number.
Wang H, Khalid MSU · Proc Inst Mech Eng G J Aerosp Eng 2026
- Crevasse Fall-Related Trauma Referred to a Swiss Level I Trauma Centre: A Retrospective Descriptive Case Series (2013-2023).
Klukowska-Rötzler J, Leuenberger I, Ziaka M · Open Access Emerg Med 2026
- The PTH responsive transcription factor NFIL3 regulates bone and energy metabolism.
Al Rifai O, St-Arnaud R · J Bone Miner Res 2026
- Accelerating High-Fidelity Airfoil Design via Physics-Informed Video Diffusion Model.
Ai Y, Guo Y, Zhang H, et al. · Adv Sci (Weinh) 2026
- Overtriage of a physician-staffed prehospital emergency resource in Austria : An exploratory retrospective analysis.
Bräu K, Welte F, Beywinkler C, et al. · Wien Klin Wochenschr 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.